Financial Avengers Inc. Purchases 6,278 Shares of Kenvue Inc. (NYSE:KVUE)

Financial Avengers Inc. increased its position in Kenvue Inc. (NYSE:KVUE) by 15.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,530 shares of the company’s stock after purchasing an additional 6,278 shares during the period. Kenvue makes up approximately 0.5% of Financial Avengers Inc.’s holdings, making the stock its 22nd biggest position. Financial Avengers Inc.’s holdings in Kenvue were worth $1,076,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Leo Wealth LLC lifted its stake in Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after acquiring an additional 481 shares during the period. Alerus Financial NA lifted its stake in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares during the period. Massmutual Trust Co. FSB ADV lifted its stake in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after acquiring an additional 492 shares during the period. Wolff Wiese Magana LLC lifted its stake in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after acquiring an additional 501 shares during the period. Finally, Marathon Capital Management lifted its stake in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after acquiring an additional 514 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.3 %

Kenvue stock opened at $22.74 on Wednesday. The firm has a 50 day moving average of $22.96 and a 200 day moving average of $21.15. The firm has a market capitalization of $43.60 billion, a price-to-earnings ratio of 41.35, a P/E/G ratio of 2.07 and a beta of 1.37. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.31 EPS. As a group, research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Wall Street Analyst Weigh In

Several research firms have issued reports on KVUE. Jefferies Financial Group began coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research note on Tuesday, September 24th. Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. increased their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.